BioReal receives Euro go-ahead for astaxanthin

By Jess Halliday

- Last updated on GMT

Related tags: Nervous system, Haematococcus pluvialis

BioReal has been given the green light to market its AstaREAL L-10
for supplements in Europe, after the astaxanthin was found to be
substantially equivalent to other sources on the market under
novels foods legislation.

Although it lags a few years behind the US and Japan, Europe is opening up as an market of potential for astaxanthin, a powerful antioxidant derived from the Haematococcus pluvialis​ microalgae.

Annual growth of the global market for astaxanthin for human use is thought to be at least 15 per cent, with current estimates valuing the market at $15-20m (€12.4-16.6m) per year.

The Swedish-based company recently expanded its production capacity in order to meet demand, with the installation of new bioreators in which the algae is grown under intensive, fully-controlled conditions.

It now has the capacity to produce "several tonnes of biomass per year".​ åke Lignel, general manager of BioReal Sweden, told NutraIngredients.com that the notification, filed on May 17, has been transferred to all member states and there has been no objections raised.

"BioReal can therefore now offer natural astaxanthin as either algal biomass or as an oleoresin extract,"​ he said.

Lignell said that Fuji Chemical Group, of which Bioreal Sweden is the European branch, is the only company that can offer algal biomass and extract approved for use in food supplements in US, Japan and Europe.

However Hawaiian-based astaxanthin producer Cyanotech has also applied for substantial equivalence approval in Europe for its product, and last month the UK Food Standards Agency' independent Advisory Committee on Novel Foods and Processes called for views on the application.

Fuji has world patents for the use of astaxanthin in physical and muscle endurance, gastric health, fertility and for the immune system disorder Crohn's disease. It also has a patent pending for eye fatigue and visual acuity.

Valensa (formerly US Nutra) holds both US and world patents for its use in retarding and ameliorating central nervous system and eye damage, and Cyanotech holds three patents - for carpal tunnel syndrome, for cold and canker sores, and as an internal and topical sunblock to prevent skin damage from UV radiation.

Related news

Show more

Related products

show more

OPUNXIA ORGANIC FOR PEOPLE AND PLANET WELLNESS

OPUNXIA ORGANIC FOR PEOPLE AND PLANET WELLNESS

BIONAP Srl | 28-Oct-2021 | Data Sheet

OPUNXIA™ has a high concentrated and standardized polysaccharides profile. It is produced in powder form through specialized technologies to ensure the...

eldosamb® the ingredient for immune power

eldosamb® the ingredient for immune power

Anklam Extrakt GmbH | 25-Oct-2021 | Research Study

eldosamb®, an anthocyanin-enriched elderberry extract, revealed its excellent potential as ingredient for immune health products. The preclinical research...

Botanical extracts from the Mediterranean rim

Botanical extracts from the Mediterranean rim

Robertet Health & Beauty | 28-Sep-2021 | Product Brochure

The Mediterranean rim is one of earth’s most biologically rich terrestrial regions. It induces a special flora, with arborescent crops and evergreen trees...

Related suppliers

Follow us

Products

View more

Webinars